The Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

Official title:

A Study Comparing the Gene Profiles of Primary and Heterogeneous Metastases of Colorectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04230018
• Other study ID #: Gene primary versus metastases
• Status: Recruiting
• Start date: December 28, 2018
• Est. completion date: December 27, 2021

Study information

• Verified date: January 2020
• Source: Sun Yat-sen University
• Contact: Feng Wang, PhD
• Phone: 86-2087343795
• Email: wangfeng[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.In patients with synchronous metastatic colorectal cancer, RAS status is highly consistent in primary focus and metastasis, so NCCN guidelines recommend RAS testing of primary or metastatic tissue is feasible .However, there are also some reports that the difference of RAS status between primary and metastatic lesions was up to 22%.In additiont,there are few studies on whether the gene profile of the metastatic lesion is the same as that of the primary lesion in patients with postoperative heterogeneous metastasis in patients with stage III colorectal cancer.

Description:

The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents. Now NCCN guidelines recommend targeted drugs for the treatment of metastatic colorectal cancer mainly including cetuximab and panizumab whic targeting EGFR , as well as the bevacizumab and arber regofini, etc which targeing anti-angiogenic.Cetuximab and panizumab are only effective in patients with RAS wild type.

Previous studies have shown that In patients with synchronous metastatic colorectal cancer, RAS status is highly consistent in primary focus and metastasis, so NCCN guidelines recommend RAS testing of primary or metastatic tissue is feasible .However, there are also some reports that the difference of RAS status between primary and metastatic lesions was up to 22%.In additiont,there are few studies on whether the gene profile of the metastatic lesion is the same as that of the primary lesion in patients with postoperative heterogeneous metastasis in patients with stage III colorectal cancer.

Therefore, it has important clinical significance to compare the difference of gene profile between metastatic lesion and primary lesion in patients with postoperative metastasis of stage III colorectal cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 27, 2021
• Est. primary completion date: December 27, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age = 18 years old and = 75 years old, both men and women;

2. Patients must have histologically confirmed metastatic colorectal adenocarcinoma and metastases can be punctured by interventional evaluation;

3. ECOG: 0 to 2;

4. Expected survival = 12 weeks;

5. Absolute neutrophil count (ANC) = 1.5 × 109 /L; Hemoglobin = 8g / dL; Platelets =100×109/L;(According to the normal value of the clinical trial center)

6. Prothrombin time (PT) < 1.5 times the upper normal limit and thrombin time (APTT) < 1.5 times the upper normal limit;

7. Informed consent has been signed.

Exclusion Criteria:

1. Patients had surgery within three weeks will be excluded.

2. Patients have known or suspected brain metastases will be excluded.

3. Pregnant or nursing women will be excluded.

4. Patients with severe uncontrolled systemic disease, such as severe active infection, will be excluded.

5. Patients had other malignancies in the past 5 years will be excluded, except cervical carcinoma in situ or basal cell carcinoma of the skin.

6. Patients who were unable to complete the study or sign valid informed consent for medical, social or psychological reasons, which will be determined by researcher, will be excluded.

7. Organ transplant recipients who need immunosuppressive therapy will be excluded.

8. People have been known to be infected with immunodeficiency virus (HIV) or have been known to be serologically positive for HIV will be excluded.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer
• Neoplasm Metastasis

Locations

Country	Name	City	State
China	Cancer center of Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (1)

Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, Ozturk A, Esbah O, Ozatli T, Celik B, Budakoglu B, Turker I, Bal O, Turan N. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. J BUON. 2015 Jan-Feb;20(1):128-35. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	prediction accuracy of survival rate	We will use the gene mutation data and follow-up data of the patients to construct a prediction model, and the accuracy of model to anticipating the 2-year survival rate of patients will be analyzed. To analyze the relationship between different gene mutations and patients' recurrence and prognosis, and to clarify the prognostic role of new mutations in heterogeneous metastasis.	through study completion, an average of 2 years.
Primary	Mutation Consistency of metastatic and primary sites of colorectal cancer patients with postoperative metastasis	We do NGS sequencing of both the primary and metastatic tissue sample of the CRC patients. The gene mutation data will be analysis, and the percentage of same and different mutation of the samples will be compared.	through study completion, an average of 2 years.
Secondary	Mutation Consistency of tissue and blood sample	The gene mutation data will be analysis, and the percentage of same and different mutation of the samples will be reported. The consistency between the gene mutation of ctDNA test in blood and the gene mutation of tissue test is analyzed to determine whether the blood ctDNA test could replace the tissue gene test	through study completion, an average of 2 years.